AKT1 and cancer: As hyperactivation of AKT signaling causes drug resistance during cancer treatment [8], we investigated and found that combining fascaplysin with LY294002 largely reduced viability of A375 (melanoma), HCT116 (colorectal cancer), and H1975 (lung cancer) cells.